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SOX1 autoantibodies are considered markers of small cell lung cancer (SCLC) and
paraneoplastic neurological syndromes (PNS) and are usually determined by commercial
line blot in many clinical services. Recent studies suggested that SOX1 autoantibodies
also occur in patients with neuropathies unrelated to SCLC, questioning the value of
SOX1 autoantibodies as paraneoplastic biomarkers. Here, we compared the specificity
and sensitivity of a commercial line blot (Euroimmun, Lübeck, Germany) with those of an
in house cell-based assay (CBA) with HEK293 cells transfected with SOX1. Overall, 210
patients were included in the study, 139 patients with polyneuropathies without SCLC,
and 71 with disorders associated with SOX1 autoantibodies detected with the in-house
CBA. Forty one of these 71 cases had been referred to our laboratory for onconeuronal
antibody assessment and 30/71 were patients with known PNS and SCLC. None of
the patients with polyneuropathies had SOX1 autoantibodies by either line blot or CBA
(specificity of the immunoblot: 100%; 95%C.I.: 97.8–100). Among the 71 patients with
CBA SOX1 autoantibodies, only 53 were positive by line blot (sensitivity: 74.6%; 95%C.I.:
62.9–84.2). Lung cancer was detected in 37/41 (90%; 34 with SCLC) patients referred
for onconeuronal antibody assessment and 34 of them also had a PNS. Our study
confirms the association of SOX1 autoantibodies with SCLC and PNS. The line blot test
misses 25% of the cases; therefore, to minimize the frequency of false negative results
we recommend the use of a confirmatory test, such as CBA, in patients suspected to
have a SCLC-related PNS.
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INTRODUCTION
SOX1 autoantibodies are serological markers of small cell lung
cancer (SCLC).They occur in up to 15% of patients with SCLC
independently of the presence of a paraneoplastic neurological
syndrome (PNS) (1, 2). The frequency of SOX1 autoantibodies
increases to 60% in patients with SCLC and paraneoplastic
cerebellar degeneration (PCD) or Lambert-Eaton myasthenic
syndrome (LEMS) (3, 4). SOX1 was first identified as the antigen
recognized by anti-glial nuclear antibodies (AGNA) which were
characterized by immunohistochemistry showing a characteristic
pattern of reactivity with the nuclei of Bergmann glia cells (5).
SOX1 belongs to the group B of the Sry-like high mobility
group box family of proteins, which are highly expressed in the
developing nervous system and the Bergmann glia of the adult
cerebellum, and in SCLCs (6–8).
Unlike other onconeural antibodies, screening by
immunohistochemistry is not recommended for the detection
of SOX1 autoantibodies because the sensitivity is low compared
with that of immunoblot of recombinant SOX1 protein (3).
Currently, there are several commercial antibody tests based
on line blots of recombinant SOX1 but comparison with other
techniques is lacking and their sensitivity and specificity is
unknown. Recent studies using immunoblot or ELISA suggested
that SOX1 autoantibodies can occur in serum of patients with
idiopathic polyneuropathies questioning the value of SOX1
autoantibodies as biomarkers of PNS associated with SCLC
(9, 10).
In this study we assessed the specificity and sensitivity of a
commercial line blot test for SOX1 autoantibodies in a large
series of patients with several types of neuropathies or PNS. In
addition, we examined the clinical features of the patients who
were referred at our laboratory for the diagnosis of onconeural
antibodies and had SOX1 autoantibodies.
METHODS
Patients
Sera from 210 patients were investigated for the presence of SOX1
autoantibodies by a commercial line blot of recombinant SOX1
and a cell based assay (CBA) of HEK293 cells transfected with
SOX1, and the findings were used to calculate the sensitivity and
specificity of the commercial line blot test. The cohort included
three subgroups of patients: (1) 139 patients with different
types of neuropathies [41 had idiopathic sensory neuropathy,
49 chronic inflammatory demyelinating polyneuropathy (CIDP),
18 paraneoplastic neuropathy associated with tumors other
than lung, and 31 anti-MAG positive monoclonal gammopathy;
this subgroup was included because SOX2 autoantibodies have
been described in patients with paraproteinemias (11)]; (2) 30
patients with paraneoplastic LEMS, PCD, or other PNS and
SCLC with SOX1 autoantibodies that had been initially tested by
an avidin-biotin immunoperoxidase technique on nitrocellulose
filters containing purified phage plaques expressing SOX1 (these
patients were included in the initial study that reported the
characterization and clinical value of SOX1 autoantibodies) (3);
and (3) 41 patients referred to our laboratory for analysis of
onconeural antibodies and whose serum showed the presence
of SOX1 autoantibodies by CBA. The clinical information
of these 41 patients was used to assess the association of
SOX1 autoantibodies with PNS and SCLC. Serum samples
were deposited in the Biobank of the Institut d’Investigacions
Biomèdiques August Pi i Sunyer, and Hospital of Sant Pau
(Barcelona, Spain). Written informed consent for the storage and
use of the samples for research was obtained from patients or
representative family members. The study was approved by the
ethics committee of the Hospital Clínic.
Diagnostic Criteria for
SOX1 Autoantibodies
In initial studies, SOX1 autoantibodies were detected by an
avidin-biotin immunoperoxidase technique on nitrocellulose
filters with purified phage plaques expressing SOX1 (3). Samples
of 30 patients from the initial study that had been positive with
this technique were examined here with a CBA of HEK293
cells transfected with GFP tagged SOX1 (see below). All 30
samples were also found positive with the CBA assay, which we
considered the “gold standard” technique for the diagnosis of
SOX1 autoantibodies in the present study.
Cell Based Assay
HEK293 cells transfected with a plasmid containing the human
SOX1 sequence tagged with the green fluorescent protein
(GFP) sequence (Origene, RG218236) were fixed with 4%
paraformaldehyde for 10min, permeabilized with 0.3% Triton
X-100 for 5min, and subsequently incubated with patients’ sera,
diluted 1/40, in PBS-1% bovine serum albumin (BSA) overnight
at 4◦C, and a fluorescent secondary antibody diluted 1/2000
(goat anti-human Alexa Fluor 594 [Jackson ImmunoResearch,
PA, USA]) for 1 h at room temperature. Slides were thenmounted
with Prolong Gold antifade reagent (Invitrogen, Carlsbad,
CA, USA) and the reactivity visualized with an Axioscope
Zeiss microscope.
Line Blot
Serum samples were tested by the commercial immunoblot
kit EUROLINE Paraneoplastic Neurological Syndromes 12 Ag
(DL 1111-1601-7G; Euroimmun, Lübeck, Germany) following
the manufacturers’ instructions at serum dilution 1/100. Test
strips were scanned and evaluated for band intensity using
the EUROLineScan software (Euroimmun Lübeck, Germany).
Following the manufacturer’s recommendations, band intensity
values >10 were considered as SOX1 autoantibody-positive.
Results≤5 were considered negative andweak bands that showed
values between 6 and 10 (borderline range) were also evaluated
as negative.
RESULTS
All 139 sera from patients with polyneuropathies were SOX1
autoantibody-negative by the commercial line blot and SOX1
CBA. The serum of one patient with sensory neuropathy and
parotid cancer was positive by immunoblot with a score of 8
(borderline range) provided by the automated band intensity
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FIGURE 1 | (A) HEK293 cells transfected with GFP-SOX1 (green) incubated with (S1) a negative control and two sera positive for SOX1 antibodies (S2 and S3 red).
(B) The three sera were incubated with strips of the commercial immunoblot (EUROLINE Paraneoplastic Neurological Syndromes 12 antigens). Note that one of the
positive sera in the CBA assay is negative by the commercial immunoblot (strip 3).
assessment of EUROLineScan software. However, the same
serumwas negative in CBA of SOX1. In the remaining 71 patients
with CBA SOX1 autoantibodies (30 with PNS and SCLC from
the initial study and 41 referred to our laboratory for antibody
testing) the immunohistochemistry on rat cerebellar sections
showed the pattern compatible with AGNA antibodies in 50 of
60 (83%) sera, and the other 11 cases were not assessable due
to co-existence of other immunoreactivities. The line blot was
positive for SOX1 antibodies in 53 of 71 patients (74.6%) and
negative in 18 (24.4%). Ten of the 18 samples showed weak
bands of reactivity (borderline range 6–10) and the other eight
were negative (≤5) (Figure 1). No clinical differences were noted
between these patients and the 18 (25.4%) cases that were SOX1
autoantibody negative by line blot (Table 1).
The specificity of the line blot for diagnosis of SOX1
autoantibodies (proportion of samples without SOX1
autoantibodies that were also negative by the line blot) was
100% (95%C.I.: 97.8–100) and the sensitivity (proportion of
samples with SOX1 autoantibodies that were also positive in
the line blot) 74.6% (95%C.I.: 62.9–84.2). If we exclude the
30 patients with SOX1 autoantibodies that were selected from
our database of PNS, the clinical data of the remaining 41
patients whose samples were sent for onconeuronal antibody
testing confirmed the specificity of SOX1 autoantibodies for
PNS and lung cancer. Lung cancer was diagnosed in 37 of 41
(90%) patients, 34 [83%] of them SCLC. Only 2 (5%) patients
had tumors other than lung cancer (breast, prostate), and no
cancer was detected in the other two patients (5%). A PNS was
confirmed in 34 of 41 (83%) patients. Among the seven patients
without PNS, five had cancer but the cause of the neurological
symptoms was metastasis, Wernicke encephalopathy, or non-
specific complains, and the other two patients did not have
cancer and the cause of neurological symptoms (cerebellar ataxia
and fasciculations) was unclear.
DISCUSSION
The findings of this study confirm the robust association between
the occurrence of SOX1 autoantibodies and the presence of lung
cancer and show the limitations of the immunohistochemical and
line blot assays in the detection of these antibodies. Currently,
the preferred screening test for onconeural antibodies in many
diagnostic laboratories is the use of commercial line blots which
can identify multiple onconeural antibodies in the same strip.
The main advantage in using these kits is the simultaneous
assessment of multiple onconeural antibodies in a single assay.
On the other hand, when these commercial line blots are used
as the only antibody screening test, there is an increased risk,
which varies for each antibody, of reporting false positive results,
downplaying the clinical significance of the autoantibodies. For
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TABLE 1 | Demographic, clinical, and immunological data of 71 patients with
SOX1 antibodies according to the commercial immunoblot results.
Immunoblot
positive
N = 53 (75%)
Immunoblot
negative





63 (22–87) 63 (52–74) 0.93
Male/Female (%) 75/25 83/17 0.16
Cancer 52 (98) 17 (94) 0.42
SCLC 49 (94) 15 (88) 0.41
Lung or NSCLC 2 (4) 1 (6) 0.72
Other 1 (2) 1 (6) 0.40
No cancer 1 (2) 1 (6) 0.42
Paraneoplastic
syndrome
49 (92) 15 (83) 0.15
PCD 9 (18) 6 (40) 0.08
LEMS 12 (24) 2 (13) 0.36
LE 13 (27) 2 (13) 0.29
Other 15 (31) 5 (34) 0.84
Non-
paraneoplastic
4 (8) 3 (17) 0.15
Other antibodies 35 (66) 9 (50) 0.55
AGNA
immunoreactivity
38/45 (84) 12/15 (80) 0.69
example, line blot is more sensitive than immunohistochemistry
in detecting low titer Hu autoantibodies (12). However, these
low Hu antibody titers indicate the presence of a SCLC but
do not necessarily confirm that the associated neurological
symptoms are paraneoplastic (2, 12). A second limitation of
commercial line blots is that in some patients they fail to
detect the presence of onconeural antibodies, suggesting they
are negative. This is clinically important because the disorder
may no longer be considered paraneoplastic and therefore, the
search for a tumor felt to be unnecessary. Some autoantibodies
seem to be more undetected than others; for example, we
previously reported that CV2 (CRMP5) autoantibodies were
missed in 7.5% (4/53) of samples that were otherwise anti-CV2-
positive by immunohistochemistry or CBA (13). The reason
for the negative immunoblot reactivity was unclear but the
possibility of very low CV2 antibody titers and the reaction
with conformational epitopes were reasonably excluded. In this
study, we found the same problem with SOX1 autoantibodies
that were undetected in 25.4% of the samples using the
commercial line blot. This figure could be reduced to 11.3%
if we consider SOX1 autoantibody positive those cases that
showed a weak, but visible, immunoblot band (score 6–10 by
the EUROLineScan software). However, if this approach is taken
there is a risk of false positive results as demonstrated by the
weak positive sample in the group of neuropathies that was
negative by CBA. A potential solution to increase sensitivity,
keeping specificity, would be to test by CBA all samples that
show a weak band in the line blot and that are currently
considered negative.
We were unable to confirm previous findings of SOX1
antibodies in patients with non-paraneoplastic polyneuropathies
(9, 10). A study that investigated the frequency of
SOX1autoantibodies in 92 patients with paraneoplastic and
non-paraneoplastic neuropathies, found nine positive patients
and only 5 (55.5%) of them had cancer (SCLC: four patients;
bronchial carcinoid: 1) (9). SOX1 autoantibodies were detected
by immunoblot of HEK293 cells transfected with mouse SOX1
clone and the findings were not confirmed with additional
techniques (9). Although the homology between human and
mouse SOX1 proteins is high we cannot rule out that the
discordant results compared with our current findings are due to
the use of clones from different species. For example, only 60% of
patients with antibodies against human myelin oligodendrocyte
glycoprotein (MOG) react with mice MOG (14). In another
study, SOX1 autoantibodies were screened by ELISA in a series
of 1,493 patients with paraneoplastic and non-paraneoplastic
disorders. Fifteen patients (1.0%) showed anti-SOX1 reactivity
and nine of them had neuropathies. Only 6/15 patients had
cancer, none of them SCLC. However, the presence of SOX1
antibodies was not confirmed with other techniques, a usual
requirement in many ELISA assays, and the concentrations of
SOX1 antibodies were significantly lower compared with those
of controls that had PNS and SCLC, raising doubt on the clinical
significance of the findings (10).
We confirmed in the 41 samples with SOX1 autoantibodies
that were sent to our laboratory for onconeuronal
antibody assessment the robust association with SCLC.
The frequency of patients without cancer was only 4.9%,
and SCLC was detected in 83% of the patients, figures
similar to those seen with anti-Hu autoantibodies (15). In
contrast, and compared with other antibodies associated
with SCLC and PNS (Hu or CRMP5), the frequency
of patients with the final diagnosis of PNS was lower
(87%) emphasizing the need to rule out alternative
diagnoses for the neurological symptoms that may lead
to antibody testing even when the presence of cancer
is confirmed.
In summary, findings from this study reveal a diagnostic
limitation of a commercial line blot for the detection of SOX1
autoantibodies. A logical approach to circumvent this problem
would be the use of a CBA as the primary assay. However, no
commercial CBA is available, so in order to minimize the risk
of false negative results by line blot, we suggest using in-house
CBA testing (available in centers of reference) in all patients
whose samples show weak or absent reactivity with line blot but
whose clinical syndrome strongly suggest a PNS associated with
SCLC (3, 4).
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